Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

Article English OPEN
Reardon, D.A.; Dresemann, G.; Taillibert, S.; Campone, Mario; Bent, Martin; Clement, Paul; Blomquist, E.; Gordower, L.; Schultz, H.; Raizer, J.; Hau, Peter; Easaw, J.; Gil, Miguel; Tonn, J.; Gijtenbeek, A.; Schlegel, U.; Bergström, Per; Green, S.; Weir, Angela; Nikolova, Z.;
(2009)
  • Publisher: Nature Publishing Group
  • Journal: volume 101,issue 12,pages1,995-2,004issn: 0007-0920, eissn: 1532-1827
  • Related identifiers: pmc: PMC2795431, doi: 10.1038/sj.bjc.6605411
  • Subject: c-KIT | Aged | platelet-derived growth factor | Brain Neoplasms | Middle Aged | imatinib mesylate | Adrenal Cortex Hormones | Glioblastoma | Hydroxyurea | Proto-Oncogene Proteins c-kit | Clinical Studies | Antineoplastic Combined Chemotherapy Protocols | Survival Rate | Adolescent | Piperazines | Pyrimidines | Adult | Female | Humans | Male | Tumor Markers, Biological

textabstractBackground: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). Methods: A total of 231 patients with GBM at first... View more
  • References (47)
    47 references, page 1 of 5

    Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L (2004) Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 18: 409 - 414

    Apte SM, Fan D, Killion JJ, Fidler IJ (2004) Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 10: 897 - 908

    Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9: 29 - 38

    Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287 - 1295

    Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, Franceschi E (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10: 361 - 367

    Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9: 453 - 461

    Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304: 1085 - 1092

    Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA (2007) Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83: 53 - 60

    Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM (2008) Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 26: 3791 - 3796

    Dresemann G (2005) Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16: 1702 - 1708

  • Similar Research Results (2)
  • Metrics
    No metrics available
Share - Bookmark